Cocrystal Pharma, Inc. (COCP)
Stock Price:
$0.834 USD
-0.001 (-0.10%)
Updated Oct 30, 2020 4:00 PM EDT - Market closed
After-hours: $0.808 -0.026 (-3.15%) Oct 30, 6:57 PM
Key Info
| Market Cap |
55.42M |
| Revenue (ttm) |
1.91M |
| Net Income (ttm) |
-55.11M |
| Shares Out |
66.43M |
| EPS (ttm) |
-1.39 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
Oct 30, 2020 |
| Last Price |
$0.834 |
| Previous Close |
$0.835 |
| Change ($) |
-0.001 |
| Change (%) |
-0.10% |
| Day's Open |
0.810 |
| Day's Range |
0.785 - 0.840 |
| Day's Volume |
654,476 |
| 52-Week Range |
0.386 - 3.040 |
More Stats
| Market Cap |
55.42M |
| Enterprise Value |
36.73M |
| Earnings Date (est) |
Nov 17, 2020 |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
66.43M |
| Float |
46.28M |
| EPS (basic) |
-1.68 |
| EPS (diluted) |
-1.39 |
| FCF / Share |
-0.14 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
n/a |
| Payout Ratio |
n/a |
| Shares Short |
181,008 |
| Short Ratio |
0.18 |
| Short % of Float |
0.39% |
| Beta |
-0.20 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| P/FCF Ratio |
n/a |
| PS Ratio |
29.03 |
| PB Ratio |
1.57 |
| Revenue |
1.91M |
| Operating Income |
-55.14M |
| Net Income |
-55.11M |
| Free Cash Flow |
-7.28M |
| Net Cash |
18.69M |
| Net Cash / Share |
0.28 |
| Gross Margin |
134.10% |
| Operating Margin |
-2,888.63% |
| Profit Margin |
-2,886.90% |
| FCF Margin |
-381.19% |
| ROA |
-9.79% |
| ROE |
-100.68% |
| ROIC |
-11,466.80% |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Forecasts
Analyst Ratings (1)
| Buy |
1 |
| Overweight |
0 |
| Hold |
0 |
| Underweight |
0 |
| Sell |
0 |
Low
5.00
Current: $0.834
High
5.00
Target: 5.00
*Average 12-month price target from 1 stock analysts.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 |
|---|
| Revenue | 6.56 | - | - | - | 0.08 | 0.01 | - | - | 12.61 | 15.25 |
| Revenue Growth | - | - | - | - | 766.67% | - | - | - | -17.36% | - |
| Gross Profit | 6.56 | - | - | - | 0.08 | 0.01 | - | - | 2.69 | 6.83 |
| Operating Income | -48.41 | -62.92 | -8.26 | -106 | -53.95 | -5.80 | -4.08 | -2.55 | -3.89 | -0.03 |
| Net Income | -48.17 | -49.05 | -0.61 | -74.87 | -50.12 | -0.10 | -3.89 | -7.96 | -5.46 | -0.32 |
| Shares Outstanding | 31.86 | 28.01 | 24.13 | 23.52 | 21.01 | 10.89 | 1.91 | 2.05 | 1.68 | 1.49 |
| Earnings Per Share | -1.51 | -1.75 | -0.03 | -3.30 | -2.40 | -0.30 | -2.10 | -3.90 | -3.30 | -0.30 |
| Operating Cash Flow | -1.56 | -8.29 | -6.90 | -14.66 | -10.32 | -6.01 | -3.69 | -1.59 | -0.42 | -0.26 |
| Capital Expenditures | -0.15 | -0.03 | -0.04 | -0.05 | -0.34 | -0.01 | - | -0.15 | -0.58 | -0.36 |
| Free Cash Flow | -1.71 | -8.32 | -6.94 | -14.71 | -10.66 | -6.02 | -3.69 | -1.74 | -1.00 | -0.62 |
| Cash & Equivalents | 7.52 | 2.79 | 2.10 | 4.97 | 9.48 | 6.14 | 1.05 | 0.01 | 0.42 | 0.25 |
| Total Debt | 0.82 | 0.33 | 1.01 | - | - | - | - | 2.39 | 7.33 | 6.93 |
| Net Cash / Debt | 6.70 | 2.46 | 1.10 | 4.97 | 9.48 | 6.14 | 1.05 | -2.38 | -6.92 | -6.68 |
| Assets | 28.53 | 68.56 | 121 | 125 | 224 | 259 | 1.66 | 7.24 | 7.55 | 7.53 |
| Liabilities | 2.82 | 1.67 | 16.03 | 22.56 | 56.64 | 74.41 | 0.39 | 10.82 | 10.32 | 8.12 |
| Book Value | 25.71 | 66.89 | 105 | 102 | 168 | 6.65 | -8.83 | -3.58 | -2.77 | -0.59 |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
Cocrystal Pharma, Inc. |
| Country |
United States |
| Employees |
11 |
| CEO |
Gary L. Wilcox |
Stock Information
| Ticker Symbol |
COCP |
| Stock Exchange |
NASDAQ |
| Sector |
Healthcare |
| Industry |
Biotechnology |
| Unique Identifier |
NASDAQ: COCP |
Description
Cocrystal Pharma, a biotechnology company, focuses on the discovery and development of antiviral therapeutic treatments for serious and/or chronic viral diseases. It employs structure-based technologies to create antiviral drugs primarily to treat hepatitis C virus (HCV), influenza virus, coronavirus, and norovirus infections. The company develops CC-31244, a HCV non-nucleoside polymerase inhibitor that is in Phase 2a clinical trial to treat HCV infection; and CC-42344, a PB2 inhibitor that is in preclinical development trials for treating influenza infection. It is also involved in identifying and developing non-nucleoside polymerase inhibitors for norovirus infections. Cocrystal Pharma, Inc. has a license and research collaboration agreement with Merck Sharp & Dohme Corp. to discover and develop proprietary influenza A/B antiviral agents; and a license agreement with Kansas State University Research Foundation to develop antiviral compounds for the treatment of norovirus and coronavirus infections. The company is headquartered in Bothell, Washington.